Sunitinib is a class II tyrosine kinase inhibitor that is often used as a second line treatment in KIT-mutated cancers that develop resistance to imatinib (Heinrich et al, 2008; Serrano et al, 2017; reviewed in Roskoski, 2018; Corless et al, 2011).
Morales-Barrera, R, Carles, J, Suárez, C, García-Valverde, A, Olivares, D, Valverde, C, George, S, Serrano, C
Roskoski, R
Antonescu, CR, Corless, CL, Heinrich, MC, Maki, RG, Town, A, Griffith, D, Fletcher, JA, Ou, WB, Demetri, GD, Baum, CM, Huang, X, Harlow, A, Cohen, DP, Fletcher, CD, McKinley, A
© 2022 Reactome
